MedTrace Logo

TCR Modified T Cells MDG1011 in High Risk Myeloid and Lymphoid Neoplasms

NCT03503968 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2023-02-15

No results posted yet for this study

Summary

This is a multicentre, non-randomized, open-label, Phase I/II clinical trial of MDG1011, an investigational medicinal product (IMP), consisting of patient-derived autologous T cells, persistently transduced with a Preferentially Expressed Antigen in Melanoma (PRAME)-specific human leukocyte antigen (HLA)-A\*02:01-restricted T cell receptor (TCR).

Conditions

  • Safety
  • Tolerability
  • Feasibility
  • Treatment Efficacy

Interventions

DRUG

MDG1011

PRAME-T-Cell Receptor Gene Modified Autologous T Cells

OTHER

Investigator Choice therapy

Any intervention/therapy chosen by the investigator

Sponsors & Collaborators

  • Medigene AG

    lead INDUSTRY

Principal Investigators

  • Simone Thomas, PD Dr. med. · University Hospital Regensburg

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-03-27
Primary Completion
2022-06-28
Completion
2022-07-15

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03503968 on ClinicalTrials.gov